CNMD logo

CONMED Corporation Stock Price

NYSE:CNMD Community·US$1.5b Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 7 Fair Values set on narratives written by author

CNMD Share Price Performance

US$50.48
-3.95 (-7.26%)
US$45.50
Fair Value
US$50.48
-3.95 (-7.26%)
10.9% overvalued intrinsic discount
US$45.50
Fair Value
Price US$50.48
AnalystConsensusTarget US$45.50
AnalystHighTarget US$49.00
AnalystLowTarget US$36.17

CNMD Community Narratives

·
Fair Value US$45.5 10.9% overvalued intrinsic discount

Minimally Invasive Surgeries And Robotics Will Boost Global Healthcare

0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
·
Fair Value US$49 3.0% overvalued intrinsic discount

Global Aging And Minimally Invasive Trends Will Empower Future Markets

0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
·
Fair Value US$36.17 39.6% overvalued intrinsic discount

Rising Costs And Supply Risks Will Impair Future Performance

0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
US$45.5
10.9% overvalued intrinsic discount
Revenue
4.17% p.a.
Profit Margin
11.59%
Future PE
8.74x
Price in 2029
US$57.85
US$49
3.0% overvalued intrinsic discount
Revenue
4.5% p.a.
Profit Margin
10.49%
Future PE
10.31x
Price in 2029
US$62.37
US$36.17
39.6% overvalued intrinsic discount
Revenue
3.63% p.a.
Profit Margin
11.53%
Future PE
7.13x
Price in 2029
US$45.27

Trending Discussion

No trending discussion available.

Updated Narratives

CNMD logo

CNMD: Gastro Exit And Potential Sale Interest Will Shape Future Upside

Fair Value: US$45.5 10.9% overvalued intrinsic discount
3 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
CNMD logo

CNMD: Potential Sale And Surgical Reset Will Shape Next Chapter

Fair Value: US$49 3.0% overvalued intrinsic discount
1 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
CNMD logo

CNMD: Sale Hopes Will Face Debt And Execution Headwinds Through 2026

Fair Value: US$36.17 39.6% overvalued intrinsic discount
1 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Undervalued with moderate growth potential.

3 Risks
3 Rewards

CONMED Corporation Key Details

US$1.4b

Revenue

US$609.3m

Cost of Revenue

US$762.3m

Gross Profit

US$705.8m

Other Expenses

US$56.5m

Earnings

Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
n/a
1.89
55.58%
4.12%
80.0%
View Full Analysis

About CNMD

Founded
1970
Employees
3900
CEO
Patrick Beyer
WebsiteView website
www.conmed.com

CONMED Corporation, a medical technology company, develops, manufactures, and sells devices and equipment for surgical procedures. The company offers orthopedic surgery products, including BioBrace, TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-knot All-Suture Anchors, and Agro Knotless Suture Anchors, which provide clinical solutions to orthopedic surgeons for the augmentation and repair of soft tissue injuries, as well as supporting products include powered resection instruments , fluid management, and visualization systems and the related single-use products that enable surgeons to perform minimally invasive sports medicine surgeries. It also provides battery-powered, autoclavable, large, and small bone power tool systems for use in orthopedic, arthroscopic, oral/maxillofacial, podiatric, spinal, and cardiothoracic surgeries under the Hall surgical brand name. In addition, the company offers general surgery products, such as clinical insufflation systems under the AirSeal brand; smoke removal devices under the Buffalo Filter brand; endomechanical products, including the Anchor1 line of tissue retrieval bags, trocars, suction irrigation devices, graspers, scissors, and dissectors, used in minimally invasive surgeries; and electrosurgical solution comprise monopolar and bipolar generators, argon beam coagulation generators, handpieces, smoke management systems, and other accessories. Further, it provides endoscopic technologies, including therapeutic and diagnostic products for use in gastroenterology procedures, and products to treat diseases of dilation, hemostasis, biliary, stricture management, infection prevention, and patient monitoring include ECG electrodes, EEG electrodes, and cardiac defibrillation pads. It markets its products directly to hospitals, surgery centers, and other healthcare institutions, as well as through medical specialty distributors. The company was incorporated in 1970 and is headquartered in Largo, Florida.

Recent CNMD News & Updates

Seeking Alpha Aug 18

CONMED Corporation: Organic Growth Is Masked By Divestitures

Summary Conmed's headline growth appeared flat at $343 million in the last quarter, but organic growth actually increased by 6%, with the leading segment being the orthopedic surgery business. Growth was offset by the divestiture of the GI business; as a result, growth metrics look poor with a quant rating of F and below the sector growth. When I adjust for organic growth, impressive profitability, and a buyback story, Conmed stock looks highly undervalued below the sector multiple. and I am rating it a buy. Read the full article on Seeking Alpha
Narrative Update Aug 14

CNMD: Gastro Exit And Potential Sale Interest Will Shape Future Upside

Analysts have raised the implied fair value for CONMED to $45.50 from $39.60, reflecting higher Street price targets clustered around $45 after recent Q2 outperformance, one-time tariff benefits, and renewed interest from potential financial and strategic buyers. Analyst Commentary Recent research on Conmed shows a split between investors focused on potential sale value and those focused on execution risks and relative appeal within medtech.

Recent updates

No updates